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Abstract
Aims/hypothesis Tables reporting life expectancies by common risk factors are available for individuals with type 2 diabetes;
however, there is currently no published equivalent for individuals with type 1 diabetes. We aimed to develop a life expectancy
table using a recently published simulation model for individuals with type 1 diabetes.
Methods The simulationmodel was developed using data from a real-world population of patients with type 1 diabetes selected from the
Swedish National Diabetes Register. The following six important risk factors were included in the life table: sex; age; current smoking
status; BMI; eGFR; and HbA1c. For each of 1024 cells in the life expectancy table, a synthetic cohort containing 1000 individuals was
created, with other risk factors assigned values representative of the real-world population. The simulations were executed for all synthetic
cohorts and life expectancy for each cell was calculated as mean survival time of the individuals in the respective cohort.
Results There was a substantial variation in life expectancy across patients with different risk factor levels. Life expectancy of 20-year-
old men varied from 29.3 years to 50.6 years, constituting a gap of 21.3 years between those with worst and best risk factor levels. In
20-year-old women, this gap was 18.9 years (life expectancy range 35.0–53.9 years). The variation in life expectancy was a function of
the combination of risk factor values, with HbA1c and eGFR consistently showing a negative and positive correlation, respectively,
with life expectancy at any level combination of other risk factors. Individuals with the lowest level (20 kg/m2) and highest level of
BMI (35 kg/m2) had a lower life expectancy compared with those with a BMI of 25 kg/m2. Non-smokers and women had a higher life
expectancy than smokers andmen, respectively, with the difference in life expectancy ranging from 0.4 years to 2.7 years between non-
smokers and smokers, and from 1.9 years to 5.9 years between women and men, depending on levels of other risk factors.
Conclusions/interpretation The life expectancy table generated in this study shows a substantial variation in life expectancy
across individuals with different modifiable risk factors. The table allows for rapid communications of risk in an easily under-
stood format between healthcare professionals, health economists, researchers, policy makers and patients. Particularly, it
supports clinicians in their discussion with patients about the benefits of improving risk factors.
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Despite increasing gains in life expectancy, individuals with
type 1 diabetes have a life expectancy 10–12 years lower than
the general population [1, 2]. While the gap had been reduced
over the second half of the twentieth century [3], the evidence
on the continuation of this improvement in the twenty-first
century is mixed [1, 4]. Optimal control over risk factors has
been shown to reduce the occurrence of diabetes-related
adverse events [5–7] and all-cause mortality [7, 8]. The deliv-
ery of personalised risk information for patients has been
shown to be effective at improving the management of modi-
fiable risk factors in individuals with chronic diseases [9] and
likely improving patients’ acceptance of doctor-recommended
management strategies [10, 11].
Currently, risk information predominantly relates to the
risk of CVD over a 5 or 10 year period [12, 13], and includes
both risk charts [14] and risk calculators [15]. While such risk
charts assist in prescribing of medications [16], patients may
also value information on a broader range of health outcome
measures including life expectancy. Recent reviews suggest
the importance of discussions on prognosis of patients with
serious health conditions [17, 18]. For patients with type 2
diabetes, life expectancies stratified by combinations of risk
factor levels have been produced [19].
Decision aids that support patients by making their deci-
sions explicit and providing more information about options
and benefits/harms have been shown to increase patient pref-
erences for effective CVD risk-reducing strategies and
increase the number of patients choosing to start new medica-
tions for diabetes [20]. The use of visual tools such as colour-
coded charts has been shown to be associated with higher
levels of patient understanding compared with verbal and
numerical (e.g. absolute or relative percentages, frequencies)
presentations [21]. The expression of risk-related concepts in
natural units such as life expectancy is easy for patients to
interpret and has a higher level of recall compared with the
relative measure of risk [22].
There is evidence that neither type 2 diabetes-specific nor
general CVD risk algorithms adequately predict CVD risk in
individuals with type 1 diabetes [23, 24], and there are current-
ly no life expectancy tables for these patients. The recent
development of a comprehensive simulation model that was
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based on a series of type 1 diabetes-specific equations enables
the estimation of a range of end points, including risks of
CVD, amputation, hypoglycaemia, hyperglycaemia and death
[25]. This model is characterised by the multifactorial nature
of type 1 diabetes progression, a wide range of interdependent
endpoints, and complex forms of the risk equations [25].
While the direct use of such a complex model to discuss risks
with patients is impractical, it can be used to estimate life
expectancy of patients with pre-specified risk factors and
therefore enables the development of a life expectancy table.
The availability of life expectancy estimates stratified by
combinations of risk factor levels allows for efficient commu-
nications of the impact of modifications of important risk
factors in units that are understandable to patients. Such life
expectancy tables facilitate an immediate assessment of the
capacity to improve health outcomes by improving modifiable
risk factors [26]. Given the lack of a visual tool for risk
communication in type 1 diabetes, we aimed to develop a risk
factor-based life expectancy table based on a simulation
model derived from a nationwide population of patients with
type 1 diabetes [25, 27].
Methods
Study design: principles and rationale We developed a life
expectancy table for individuals with type 1 diabetes by running
simulations using our recently publishedmodel to predict surviv-
al times of individuals with specific baseline characteristics [25].
Variables required as input for the simulations included 25 risk
factors (see Table 1) and 16 other auxiliary variables such as time
since last hyperglycaemia in patients with a history of this event
(see Electronic supplementary material [ESM] Table 1). As the
number of the input variables was large, we balanced the number
of risk factors to be included in the life expectancy table with the
table size to facilitate its use in practice. Therefore, we selected
six of the most important risk factors for the table (including sex,
age, current smoking status, BMI, eGFR and HbA1c). These had
been identified in the sensitivity analyses in our previous study
[25] as being risk factors for which changes in their values had a
greater impact on life expectancy compared with other variables.
For these risk factors, we selected two levels for the binary vari-
ables and four levels for the continuous variables as follows:
& Sex: male and female
& Current age, in years: 20, 30, 40 and 50
& Current smoking status: smoker and non-smoker
& Baseline BMI, in kg/m2: 20, 25, 30 and 35
& Baseline eGFR, in ml min−1 [1.73 m]−2: 30, 60, 90 and
120
& HbA1c, in mmol/mol (%): 42 (6), 64 (8), 86 (10) and 108
(12)
The lowest and highest levels of the continuous risk factors
were selected to encompass the normal ranges of their values
and contain mean values of the population of patients with
type 1 diabetes used to develop the simulation model, referred
to as the real-world population [27] (see Table 1). With these
selected risk factors and their levels, the life expectancy table
contained 1024 cells, each representing an individual with a
unique combination of the baseline levels from six risk
factors. To execute the simulation for each individual, the risk
factors not included in the table, referred to as ‘hidden’ vari-
ables, were assigned values that represented the values of
those risk factors in the real-world population (see Table 1).
Based on this principle, we assigned mean values of the
continuous risk factors in the real-world population to the
corresponding hidden risk factors of any individual in the life
expectancy table. However, this approach was not applicable
for the binary risk factors, which could not take on values
different from the levels used in the statistical model fitting
(see Simulation model for type 1 diabetes, below, for details).
For example, 14% of the real-world population had a history
of hypoglycaemia (see Table 1); however, it was not possible
to assign the value of 0.14 to the variable indicating the history
of hypoglycaemia, as this variable could only receive a value
of 0 or 1. Therefore, for each individual in the life expectancy
table, we created a synthetic cohort containing 1000 individ-
uals in which values of the hidden binary risk factors followed
a joint distribution similar to that in the real-world population
(see Creation of the synthetic cohorts, below, for details). In
this way, mean life expectancy of a synthetic cohort represents
the life expectancy of an ‘average’ individual with respect to
the values of those binary risk factors. As a result, we created
1024 synthetic cohorts, each of which was unique in terms of
the combined levels of six risk factors but identical in values
of the other characteristics. In this way, any difference in life
expectancy between individuals in the table would be attrib-
uted only to the differences in the levels of the risk factors
included in the table. Then, we ran the simulations for all these
cohorts to estimate the life expectancies of all cells in the life
expectancy table (see Simulations and outcomes aggregation,
below, for details).
Simulation model for type 1 diabetes The simulation model
used in this study comprised 14 parametric proportional
hazards equations to estimate the risk of type 1 diabetes-
related complications and death, and ten equations to predict
changes over time in risk factors of the patients [25]. These
equations were developed using data from the real-world
population selected from the Swedish National Diabetes
Register [27]. To minimise the risk of including individuals
with type 2 diabetes, only those who were younger than
30 years of age at diabetes diagnosis and had at least one
prescription of insulin annually and no prescriptions for
metformin were included in the study cohort. The exclusion
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of metformin prescriptions was due to the infrequent use of this
medication in the treatment of patients with type 1 diabetes in
Sweden. As a result, the population used for the model develop-
ment contained 27,841 individuals with type 1 diabetes, recorded
between 1 January 2002 and 31 December 2011, with a mean
follow-up time of 7 years. Predictors in the equations for risk and
risk progression were selected from 41 potential variables plus
variables representing the interaction effects between patient
characteristics and age. Except for BMI, all the categorical
predictors were binary variables. These categorical variables
were coded as dummy variables, with 0 indicating the reference
and 1 indicating the level compared with the reference.
For the statistical analyses, all HbA1c values were convert-
ed to standard levels according to the US National
Glycohemoglobin Standardization Program [28]. Values of
eGFR were calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation [29]. All equations for
risk and risk factor progression were internally validated by
comparing the predictions and observed data, with the results
showing that there was a high agreement between the simu-
lated and observed values (see our previous publication:
Figure 2 in the main text and Figure S2 in the supplementary
material [25]). A full description of the simulation model,
including the identification of the events, the definitions of
the risk factors, the equations and the validation exercises,
can be found in our previous study [25]. Briefly, the model
predicts occurrence of the following events: fatal and non-
fatal myocardial infarction; fatal and non-fatal stroke; heart
Table 1 Baseline characteristics of individuals with type 1 diabetes in the real-world population (n = 27,841) used to develop the synthetic cohorts
Characteristic Real-world population
baseline value
Used in the synthetic cohort and life expectancy
table development
Male sex, n (%) 15,492 (55.6) Separate cohorts for men and women; risk factor
displayed in the life expectancy table
Current smoker, n (%) 3783 (13.6) Separate cohorts for smokers and non-smokers; risk factor
displayed in the life expectancy table
Age, years 36.98±14.94 Mean value within the range from lowest level to highest
level for each risk factor; risk factors displayed
in the life expectancy table
BMI, kg/m2 24.90±3.71
eGFR, ml min−1 [1.73 m]−2 96.05±26.52
HbA1c, mmol/mol 65±13
HbA1c, % 8.10±1.38
Age at onset, years 15.01±7.60 Mean values assigned to each individual in any
synthetic cohort; risk factors hidden in the
life expectancy table




Former smoker, n (%) 1202 (4.3) Joint distribution of the proportions used to sample the
values of these risk factors; risk factors hidden in
the life expectancy table
Microalbuminuria, n (%) 5848 (21.0)
Macroalbuminuria, n (%) 2299 (8.3)
History of MI, n (%) 802 (2.9)
History of stroke, n (%) 488 (1.8)
History of CHF, n (%) 365 (1.3)
History of PCI, n (%) 389 (1.4)
History of CABG, n (%) 692 (2.5)
History of angina, n (%) 273 (1.0)
History of PVD, n (%) 1035 (3.7)
History of amputation, n (%) 1156 (4.2)
History of hypoglycaemia, n (%) 3898 (14.0)
History of hyperglycaemia, n (%) 3941 (14.2)
History of ESRD, n (%) 154 (0.6)
Values are presented as means±SD or n (%)
CABG, coronary artery bypass graft; CHF, congestive heart failure; ESRD, end-stage renal disease; MI, myocardial infarction; PCI, percutaneous
coronary intervention; PVD, peripheral vascular disease
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failure; peripheral vascular disease; hypoglycaemia;
hyperglycaemia; amputation; end-stage renal disease; percu-
taneous coronary intervention; coronary artery bypass graft;
and all-cause death. The model also simulates changes over
time in the values of the following risk factors: HbA1c; BMI;
systolic BP; triacylglycerols; HDL-cholesterol; LDL-choles-
terol; eGFR; smoking status; microalbuminuria; and
macroalbuminuria. The model was structured to capture the
interdependencies between risk factor progression, histories of
complications and future occurrence of complications and
death, which were necessary for an unbiased estimation of life
expectancy.
Creation of the synthetic cohorts As mentioned earlier, 1024
synthetic cohorts were created, each represented by an indi-
vidual with a unique combination of the levels of the risk
factors included in the life expectancy table. The dataset for
each cohort was constructed to contain 1000 observations and
all variables (i.e. predictors) required to execute the equations
for risk and risk factor progression. Four categories of predic-
tors were taken into consideration in the setting of their values:
(1) risk factors included in the life expectancy table, which
were assigned the pre-specified levels; (2) binary variables not
included in the life expectancy table, which were assigned
values sampled using the joint Bernoulli distributions of these
variables in the real-world population; (3) continuous vari-
ables not included in the life expectancy table, which were
assigned mean values of these variables in the real-world
population; and (4) variables representing the interaction
effects between age and the variables in the first three
categories.
The binary variables included those indicating histories of
complications, microalbuminuria and macroalbuminuria, and
the number of prior complications (see Table 1 and ESM
Table 1). Our previous study [25] showed that the occurrence
of a complication influenced the subsequent occurrence of other
complications; therefore, we sampled the histories of the
complications using a joint distribution, and microalbuminuria
and macroalbuminuria using another joint distribution to partly
capture the interdependencies between them. The sampling of
the values of a set of interdependent variables was carried out as
follows. First, we identified every unique combination of the
values of these variables in the real-world population and asso-
ciated each unique combination with a unique identifier. Then,
we assigned each observation in the real-world population with
an identifier corresponding to the combined values of the vari-
ables in that observation. Next, we calculated the proportions of
the population with different identifiers, which represented the
probability mass function of the identifiers. Based on the prob-
ability mass functions, we constructed the cumulative distribu-
tion function of the identifiers, and used this to sample the
identifiers based on the inverse transform method [30].
Finally, we assigned the variables in the synthetic cohort with
the values corresponding to the sampled identifiers. After the
continuous variables were assigned values and the binary vari-
ables were sampled, the variables representing the interaction
effects between those variables and age were created and their
values calculated to complete the set of predictors in each
synthetic cohort.
Simulations and outcomes aggregation For each synthetic
cohort, we ran the simulation until all individuals had died.
During the simulation, the occurrence of the events and changes
in risk factor values were predicted in annual cycles using the
equations for risk and risk factor progression as described above.
The remaining life expectancy of an individual was defined as
time from the baseline age to death. Details of the simulation
process can be found in our previous publication [25]. To reduce
the first-order (stochastic) uncertainty, which relates to the fact
that individuals with identical characteristics may experience
different outcomes, we repeated the simulation for each cohort
100 times and calculated the life expectancy of each individual as
mean across 100 replications. We then calculated mean life
expectancy and its SD based on the life expectancies of 1000
individuals in each cohort, to represent the life expectancy and its
variation for an average person in that cohort. Then, we created a
table with 1024 cells, each of which displays the life expectancy
corresponding to a unique combination of risk factor levels. The
table was colourised to display a gradient of the outcomes within
each age and sex stratum (considered as non-modifiable risk
factors), in which green represents better outcomes and red
worse.
We used the model developed in Stata 15.0 (StataCorp,
College Station, TX, USA) to run the simulations, and R
version 4.02 (R Foundation for Statistical Computing,
Vienna, Austria) [31] to create the synthetic cohorts and
compile the simulated outcomes.
Results
Figure 1 provides life expectancies of 1024 patients with
specific risk factor levels and Fig. 2 provides the SEs of these
life expectancies. There was a substantial variation in life
expectancy across individuals with different risk factor levels.
For example, life expectancy of 20-year-old men varied from
29.3 years to 50.6 years, constituting a gap of 21.3 years
between those with worst and best risk factor levels. In 20-
year-old women, this gap was 18.9 years (life expectancy
range 35.0–53.9 years).
The variation in life expectancy was a function of the
combination of risk factor values, with HbA1c and eGFR
consistently showing a negative and positive correlation,
respectively, with life expectancy at any level combination
of other risk factors. Individuals with the lowest level
(20 kg/m2) and highest level of BMI (35 kg/m2) had a lower





































































20 25 30 35 20 25 30 35 20 25 30 35 20 25 30 35 20 25 30 35 20 25 30 35 20 25 30 35 20 25 30 35
36.8 45.3 45.0 44.8 29.6 37.1 36.4 36.6 23.0 29.1 28.0 28.1 16.8 21.8 20.3 20.5 41.8 49.1 48.9 49.1 33.6 40.2 39.7 39.8 25.6 31.8 30.8 31.2 18.9 24.0 22.6 22.8
38.9 47.2 46.6 46.9 31.6 38.7 37.7 38.1 24.8 30.5 29.5 29.6 18.0 23.1 21.6 22.0 43.8 50.6 50.5 50.6 35.2 41.6 41.3 41.4 27.3 33.2 32.0 32.5 20.4 25.1 23.9 24.2
41.4 48.9 48.4 48.5 33.5 40.1 39.5 39.7 25.9 32.1 31.0 31.0 19.4 24.3 22.9 23.0 45.9 52.1 52.1 52.3 37.3 43.2 42.7 42.8 28.8 34.5 33.4 33.8 21.4 26.5 25.3 25.5
43.7 50.6 50.4 50.4 35.0 41.8 41.1 41.2 27.5 33.6 32.2 32.5 20.6 25.8 24.3 24.6 47.8 53.9 53.6 53.8 38.6 44.5 44.2 44.4 30.1 36.1 34.9 35.0 22.7 27.7 26.6 26.5
36.6 44.8 44.4 44.5 29.0 36.5 35.7 35.8 22.3 28.5 27.3 27.4 16.2 21.1 19.7 19.9 41.5 48.9 48.4 48.5 33.0 39.8 39.2 39.3 25.4 31.4 30.3 30.6 18.3 23.6 22.3 22.2
38.3 46.6 46.2 45.9 30.6 37.9 37.2 37.6 23.9 29.9 29.0 29.0 17.7 22.4 21.1 21.3 43.3 50.1 50.0 50.0 35.0 41.1 40.7 40.8 26.9 32.8 31.6 32.0 19.8 24.7 23.4 23.4
40.7 48.3 47.9 48.1 33.0 39.6 38.8 38.9 25.3 31.3 30.2 30.3 18.9 23.9 22.6 22.5 45.2 51.5 51.4 51.7 36.5 42.7 42.2 42.2 28.4 34.0 33.2 33.0 21.0 26.2 24.6 24.9
42.9 49.9 49.6 49.6 34.6 41.2 40.4 40.5 26.9 32.9 31.9 31.8 20.3 25.2 23.9 24.0 47.1 53.1 53.0 53.4 38.1 44.1 43.4 43.8 29.6 35.5 34.4 34.6 22.4 27.3 26.0 26.0
35.2 43.5 43.0 42.7 27.9 35.1 34.5 34.4 21.2 27.3 26.2 26.1 15.4 20.1 19.1 18.9 40.2 47.6 47.4 47.3 31.7 38.7 38.1 37.9 24.2 30.4 29.3 29.3 17.4 22.6 21.4 21.2
37.2 44.9 44.7 44.4 29.6 36.8 35.9 35.9 22.6 28.7 27.8 27.6 16.7 21.6 20.1 20.3 41.9 48.9 48.9 48.8 33.6 40.0 39.4 39.5 25.8 31.5 30.5 30.8 18.9 23.7 22.6 22.6
39.1 46.5 46.4 46.4 31.5 38.2 37.4 37.3 24.2 30.2 29.0 29.0 17.9 23.0 21.6 21.6 43.9 50.3 50.2 50.1 35.1 41.4 40.8 40.8 27.3 32.9 32.1 32.2 20.3 25.1 23.9 23.8
41.2 48.5 48.2 47.9 33.0 39.9 39.1 39.1 25.8 31.6 30.5 30.7 19.2 24.2 23.1 22.8 45.9 51.9 51.6 51.9 37.0 43.1 42.3 42.6 28.6 34.3 33.5 33.3 21.4 26.2 25.2 25.2
30.1 38.3 38.6 37.7 23.7 30.8 30.7 30.0 18.2 24.0 23.2 22.9 13.1 17.7 16.6 16.5 35.8 43.3 43.4 42.9 28.0 35.0 34.5 34.1 21.3 27.3 26.4 26.1 15.4 20.1 18.9 18.9
31.8 39.9 40.1 39.5 25.4 32.7 32.3 31.4 19.6 25.3 24.6 24.3 14.2 18.9 17.9 17.8 37.7 44.8 44.8 44.6 29.5 36.4 36.1 35.7 22.8 28.5 27.7 27.5 16.5 21.3 20.3 20.2
33.9 41.9 41.8 40.9 27.3 34.3 33.7 33.2 21.2 27.1 26.1 25.6 15.7 20.2 19.2 18.9 39.0 46.6 46.6 46.0 31.3 37.9 37.5 37.3 24.0 30.0 29.1 28.8 17.7 22.5 21.5 21.4
36.1 43.9 43.9 43.5 28.8 36.0 35.6 35.1 22.5 28.2 27.7 27.2 16.8 21.7 20.7 20.3 41.3 48.4 48.2 47.6 32.9 39.7 39.2 38.9 25.7 31.1 30.6 30.3 18.9 23.8 22.8 22.6
34.2 43.7 43.0 43.1 26.9 35.2 34.3 34.4 20.3 27.0 25.7 25.9 14.4 19.7 18.0 18.0 40.0 47.9 47.5 47.6 31.5 39.0 38.0 38.1 23.6 30.1 28.9 29.0 16.6 22.0 20.3 20.6
37.2 45.4 45.1 45.0 29.3 37.2 36.3 36.2 22.2 28.7 27.4 27.5 16.0 21.0 19.7 19.6 42.1 49.5 49.3 49.4 33.5 40.4 39.8 39.9 25.4 31.5 30.4 30.4 18.2 23.2 21.9 22.0
39.6 47.3 47.0 47.1 31.5 38.7 37.7 37.9 24.0 30.3 28.9 29.1 17.5 22.6 21.1 21.2 44.5 51.1 51.0 51.2 35.7 42.2 41.3 41.5 27.1 33.1 32.1 32.1 19.5 24.8 23.2 23.4
41.9 49.5 49.1 49.1 33.7 40.5 39.5 39.8 25.6 31.9 30.6 30.8 18.9 23.8 22.3 22.8 46.7 52.9 52.5 52.8 37.4 43.5 42.9 43.0 28.8 34.5 33.2 33.6 20.8 26.3 24.6 25.1
34.4 43.2 42.8 42.5 26.9 34.7 33.7 33.8 19.9 26.5 25.0 25.1 14.2 19.0 17.4 17.6 40.1 47.5 47.2 47.2 31.1 38.3 37.7 37.8 23.3 29.5 28.2 28.4 16.3 21.4 20.1 20.0
36.8 45.0 44.7 44.6 29.1 36.5 35.5 35.6 21.7 28.1 26.9 26.9 15.5 20.2 18.9 19.1 42.0 49.0 48.5 49.0 32.8 39.7 39.4 39.5 24.7 31.2 29.8 30.0 17.6 22.9 21.3 21.5
39.0 46.9 46.7 46.5 30.8 37.9 37.1 37.5 23.4 29.6 28.4 28.5 16.9 22.0 20.7 20.5 44.2 50.6 50.6 50.7 35.1 41.4 40.8 40.8 26.7 32.5 31.3 31.6 19.0 24.2 22.6 22.9
41.6 48.8 48.4 48.6 33.0 39.8 38.9 39.1 24.9 31.2 29.9 30.2 18.4 23.5 21.8 22.1 45.8 52.2 52.2 52.4 36.8 43.0 42.3 42.4 28.3 34.0 32.7 33.1 20.5 25.6 24.3 24.4
33.2 42.1 41.7 41.4 26.0 33.3 32.8 32.4 18.9 25.3 24.1 24.1 13.2 18.0 16.6 16.6 38.7 46.5 46.2 46.0 30.1 37.3 36.8 36.6 22.1 28.4 27.2 27.3 15.3 20.3 19.0 19.1
35.6 44.0 43.5 43.2 27.8 35.2 34.4 34.1 20.8 26.9 25.6 25.7 14.6 19.5 18.0 18.0 40.7 47.9 48.0 47.7 32.1 38.8 38.0 38.1 23.9 30.0 28.8 29.1 16.8 21.9 20.5 20.5
37.8 45.7 45.2 45.1 29.7 36.4 35.9 36.0 22.3 28.6 27.4 27.1 16.1 21.0 19.4 19.7 43.0 49.5 49.4 49.3 33.7 40.2 39.7 39.7 25.4 31.4 30.3 30.4 18.2 23.2 21.9 21.9
39.9 47.4 47.0 47.0 31.5 38.5 37.8 37.5 23.8 29.9 28.8 28.7 17.4 22.5 20.9 20.9 44.8 51.2 51.0 51.1 35.7 41.9 41.1 41.1 27.1 33.0 31.9 32.0 19.6 24.6 23.3 23.4
29.3 37.8 37.5 37.0 22.1 29.4 28.9 28.6 16.3 22.0 21.3 20.7 11.3 15.6 14.2 14.3 35.0 42.8 42.9 42.3 26.4 33.7 33.4 32.8 19.3 25.4 24.5 24.1 13.3 17.9 16.9 16.6
31.1 39.4 39.3 38.5 24.0 31.2 30.5 30.3 17.7 23.7 22.9 22.6 12.5 17.0 15.9 15.7 36.5 44.2 44.4 43.8 28.2 35.3 34.9 34.7 21.0 27.1 26.0 26.0 14.6 19.5 18.2 18.1
33.1 41.2 41.0 40.3 25.6 32.9 32.4 32.1 19.3 25.3 24.3 24.1 13.9 18.3 17.4 17.3 38.6 45.9 45.9 45.4 30.0 37.0 36.7 36.2 22.7 28.4 27.6 27.4 15.9 20.7 19.6 19.5
35.1 43.3 43.0 42.5 27.6 34.6 34.3 33.7 20.8 26.9 25.8 25.3 15.1 19.8 18.6 18.5 40.7 47.7 47.5 47.2 32.3 38.7 38.3 37.9 24.1 30.0 29.2 29.0 17.3 22.3 21.1 20.8
BMI BMI BMI
FemaleMale
Age 20 Age 30 Age 40 Age 50 Age 20 Age 30 Age 40 Age 50







Fig. 1 Life expectancy of individuals with type 1 diabetes and with
specific baseline levels of sex, age (years), BMI (kg/m2), current smoking
status, eGFR (ml min−1 [1.73 m]−2) and HbA1c (mmol/mol). The colour
gradient within each age–sex stratum goes from green (higher life expec-
tancy) to dark red (lower life expectancy). Value in each cell represents
the number of years from the baseline age to death
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Fig. 2 SEs of the life expectancies of individuals with type 1 diabetes and
with specific baseline levels of sex, age (years), BMI (kg/m2), current
smoking status, eGFR (ml min−1 [1.73 m]−2) and HbA1c (mmol/mol).
The colour gradient within each age–sex stratum goes from green (larger
SEs) to dark red (smaller SEs). This figure complements Fig. 1
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life expectancy compared with those with a BMI of 25 kg/m2.
Non-smokers and women had a higher life expectancy than
smokers and men, respectively, with the difference in life
expectancy ranging from 0.4 years to 2.7 years between
non-smokers and smokers, and from 1.9 years to 5.9 years
between women and men, depending on levels of other risk
factors.
Figure 1 can be used to estimate the benefits associated
with the differences in lifestyle factors. For example, a male
aged 30 years, with eGFR of 30mlmin−1 [1.73m]−2, whowas
a smoker, and had a BMI of 35 kg/m2 and an HbA1c of
108 mmol/mol (12%) would have a life expectancy of
28.6 years. However, if the HbA1c of this individual was
lowered to 42 mmol/mol (6%), his life expectancy would
increase to 33.7 years; in addition to this HbA1c lowering, if
the eGFR was increased to 120 ml min−1 [1.73 m]−2, his life
expectancy would further increase to 39.8 years. In addition to
these improvements in HbA1c and eGFR, if BMI were
reduced to 25 kg/m2 then life expectancy would further
increase to 40.5 years, and if the person were a non-smoker
the life expectancy would be 41.8 years. The gain in life
expectancy associated with the combined improvement of
the above-mentioned risk factors would be 13.2 years in this
instance.
Another version of the life expectancy table, using a
greyscale-based gradient, is provided in ESM Fig. 1.
Figures representing age at death are also provided in ESM
Fig. 2 (colourised within each age and sex stratum) and ESM
Fig. 3 (colourised across the whole population). An interactive
web application for the life expectancy table is available at
https://antranduy.shinyapps.io/le-t1d/. This application is
best viewed on a full HD widescreen computer monitor.
Discussion
We have generated an age- and sex-stratified life expectancy
table that demonstrates the impact of different combinations
of risk factor levels on life expectancy in individuals with type
1 diabetes. This adds to the existing literature by providing
estimates of the impact of bothmodifiable and non-modifiable
variables on the average life expectancy. Our results are
presented in a similar format to other risk and life expectancy
tables that are widely used [19, 32, 33], in which various
combinations of risk factors organised by columns and rows
permit specific life expectancies to be read from the table.
Using our table, the life expectancy of a 20-year-old man
with type 1 diabetes was between 29.3 years and 50.6 years,
and that of a 20-year-old woman between 35.0 years and
53.9 years. These life expectancies were substantially lower
than the 59.4 and 63.3 years for 20-year-old men and women,
respectively, derived from the Swedish general population in
2007 [34]. We found large variations in life expectancies of
individuals with the same non-modifiable variables (i.e. sex or
age), as well as the same levels of modifiable variables such as
HbA1c, eGFR, BMI and smoking status. Changes in the levels
of modifiable variables accounted for the broad range of
possible life expectancies reported.
The life expectancy table we generated provides perti-
nent information on a patient’s prognosis, as well as poten-
tial life expectancy gains associated with improvement of
important risk factors. This information is valuable to
patients and clinicians in setting a goal for changing life-
style and treatment. These results clearly demonstrate the
potential for increasing life expectancy by improving
levels of modifiable risk factors. This information may also
be used in other fields (e.g. insurance companies could use
our life expectancy table to calculate annuities for individ-
uals with type 1 diabetes [35]). It should be noted that the
estimated life expectancies are conditional on an individual
surviving to the baseline age presented in the table. As a
result, mean age at death (current age plus life expectancy)
increased with increasing baseline age in individuals with
identical levels of other risk factors (see ESM Fig. 2). This
is because a younger individual would be at risk for a
number of years before he/she reached the older baseline
age. Therefore, one should not make the interpretation that
an older patient is ‘healthier’ than a younger one with
identical risk factors.
A substantial gap in life expectancy between individuals
with type 1 diabetes and the general population has been
reported on a number of occasions [1]. Recent reports [36]
indicate that infectious diseases such as coronavirus disease-
2019 (COVID-19) have a disproportionate impact on individ-
uals with type 1 diabetes, with a potential 3.5-fold increase in
risk of dying in hospital with COVID-19. Our risk factor
stratified life expectancy table can support the estimation of
the burden of type 1 diabetes, as well as the potential loss from
emerging diseases such as COVID-19.
The life expectancy table developed in this study allows for
assessment of the impact of six important risk factors. It is
possible to expand this table to include more risk factors
(e.g. lipid levels) and increase the number of levels for each
continuous risk factor. However, the use of a table with sever-
al thousands of cells may not be practical. In this eventuality,
the availability of an electronic life expectancy calculator
would be extremely helpful, and development of such a calcu-
lator is an objective for our future work.
Strengths and limitations This is the first study that developed
a life expectancy table for individuals with type 1 diabetes.
The analysis was based on a comprehensive simulation model
derived from a large type 1 diabetes registry population [25].
The data were collected prospectively and had a high level of
coverage across the Swedish national diabetic population. The
registry contains detailed information on clinical
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characteristics and laboratory measures which were used in
this study for the development of the synthetic cohorts. The
simulation model [25] has been internally validated, with the
predicted event rates closely matching those observed in the
real-world population.
Our study has limitations. The data used to develop the
simulation model were recorded between 1 January 2002
and 31 December 2011. Therefore, the overall secular trend
of reduced mortality and the type 1 diabetes-specific improve-
ment in life expectancy in the period after 2011 was not
captured in the model [25]. As a consequence, the life expec-
tancies estimated in this study might be slightly lower than
those of the current patients. It is therefore important to regu-
larly update the equations in the simulation model using more
recent data and to use the updated simulation model to re-
estimate the life expectancies in the table.
Due to the observational nature of the registry data, the
equations in the simulation model [25] describe associations
and not necessarily a causal link between the predictors and
the outcomes. Therefore, care should be taken when making
causal assumptions about the impact of changes in risk factors
on the life expectancies in the table. Although the simulation
model used to estimate the life expectancies was internally
validated, it has not been externally validated using datasets
other than the Swedish National Diabetes Register [27].
Therefore, it is currently unclear whether the life expectancies
we estimated also represent those of patients with type 1
diabetes in geographical regions other than Sweden.
Conclusions The life expectancy table generated in this study
shows a substantial variation in life expectancy across individuals
with different modifiable risk factors. This indicates a large scope
for increasing life expectancy via optimisation of the risk factor
levels. The table allows for rapid communications of risk in an
easily understood format between healthcare professionals,
health economists, researchers, policy makers and patients.
Particularly, it supports clinicians in their discussion with the
patients about benefits of improving risk factors in terms years
of life gained, an important outcome measure to the patients.
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